Mammalian milk osteopontin for enhancing immune responsiveness

Patent metadata

Field	Value
Publication number	US-10772955-B2
Application number	US-201815945517-A
Country	US
Kind code	B2
Filing date	Apr 4, 2018
Priority date	Jul 5, 2013
Publication date	Sep 15, 2020
Grant date	Sep 15, 2020

Abstract

The disclosed invention provides mammalian milk osteopontin and/or an active truncation or active peptide thereof for improving immune responsiveness to an infectious disease in a mammal, for example a human subject, as well as enhancing the efficacy of vaccination for the prophylactic or therapeutic treatment of an infectious disease in mammals, such as humans. The invention further provides a vaccine system, for use in the prophylactic or therapeutic treatment of an infectious disease in a mammal, comprising a vaccine and a mammalian milk osteopontin and/or an active truncation or active peptide thereof for oral administration to a mammal, as well as methods of enhancing immune resistance to an infectious disease in a mammal by administration of a vaccine and a mammalian milk osteopontin and/or an active truncation thereof.

First claim

The invention claimed is:

1. A nutritional composition for use in preventing or treating infectious disease, wherein the composition:
comprises about 0.01 to about 90% w/w of bovine milk osteopontin over the composition, wherein:
(a) the bovine milk osteopontin is an enriched source of purified bovine milk osteopontin having at least 80% purity;
(b) the bovine milk osteopontin comprises, in a ratio of between about 70:30 to about 80:20, a full-length osteopontin polypeptide amino acid sequence comprising residues 17-278 of SEQ ID NO: 1 and an active truncated osteopontin polypeptide of 40 kDa formed by cleavage at a position that is C-terminal to the RGD motif of full-length osteopontin.

2. The nutritional composition of claim 1 , comprising about 0.1 to about 80% w/w of bovine milk osteopontin.

3. The nutritional composition of claim 2 , comprising about 1 to about 70% w/w of bovine milk osteopontin.

4. The nutritional composition of claim 1 , wherein the composition contains bovine milk osteopontin in the range of about 0.1 mg to about 10 grams.

5. The nutritional composition of claim 4 , wherein the composition contains bovine milk osteopontin in the range of about 10 mg to about 800 mg.

6. The nutritional composition of claim 1 , wherein the composition is in liquid form or powdered form.

7. The nutritional composition of claim 1 , wherein the amino acid sequence of the active truncated bovine milk osteopontin polypeptide comprises residues 17-163 of SEQ ID NO:1.

8. The nutritional composition of claim 1 , wherein the purity of the bovine milk osteopontin is at least about 80% to about 90% or about 90% to about 95%.

9. The nutritional composition of claim 8 , wherein the bovine milk osteopontin is about 95% pure, about 96% pure, about 97% pure, about 98% pure, about 99% pure, or about 99.5% pure.

Assignees

• Arla Foods Amba

Inventors

• Kvistgaard Anne Staudt
• Wejse Peter Langborg
• Donovan Sharon
• Siegel Marcia H Monaco
• Comstock Sarah S

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A23L33/19 Primary

  Dairy proteins · CPC title

• A61K38/17 Primary

  from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title

• A61K39/39 Primary

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title